FDA Briefing
Document
for the
Anti-Infective Drug Products Advisory Committee
Artesunate Rectal
Capsules
World Health
Organization
NDA 21-242
July 10, 2002
Food and Drug
Administration
Center for Drug Evaluation
and Research
Division of Special Pathogen and Immunologic Drug Products
Table of Contents
Background.......................................................................................................................... 1
Efficacy............................................................................................................................. 1
Safety............................................................................................................................... 2
Alternative treatments........................................................................................................ 2
Issues related to the
study of rectal Artesunate in patients with acute malaria........................... 3
Pharmacotoxicology.............................................................................................................. 6
Microbiology......................................................................................................................... 9
Clinical Issues...................................................................................................................... 16
Efficacy........................................................................................................................... 16
Pivotal studies............................................................................................................. 16
Additional supportive
studies....................................................................................... 23
Safety............................................................................................................................. 23
Summary of data
presented to the Chinese regulatory authorities................................... 23
Summary of a systemic
review of published and unpublished data................................. 23
Summary of WHO-specific
studies in the NDA submission.......................................... 23
Special populations.................................................................................................. 23
Neurotoxocity......................................................................................................... 23
(The reader is referred to the briefing package provided by WHO. This
document provides a detailed perspective on the problem of malaria in endemic
regions of the world and the potential role of rectal artesunate in malaria
control).
Rationale for developing rectal artesunate:
In malaria endemic regions of the world, Plasmodium falciparum is responsible for hundreds of thousands of deaths, especially among children. One of the most important reasons for the very high malaria mortality is the delay in receiving effective medication. Unfortunately, many patients with acute malaria are unable to tolerate oral therapy. Consequently, parenteral treatment is usually necessary, and this may only be available at clinics or hospitals. These facilities are often difficult to reach because of long distances and poor infrastructure in terms of roads and transport.
The aim of the applicant was to develop a product that could be administered on an emergency basis to patients too ill to take anything orally.
The goal was to reduce mortality by early intervention in the field, providing some cover over the first 24 hours to allow patients to reach definitive treatment.
An artemisinin derivative for rectal administration was selected as a suitable candidate.
Artemisinin derivatives have been used for many years as antimalarial agents in Asia. Published literature indicates that artemisinins given orally or parenterally are effective in causing rapid decreases in the parasite count in smears of peripheral blood. They are used extensively in areas of the world where P. falciparum shows resistance to quinine, and they are reportedly effective in quinine-resistant infections.
Artesunate is rapidly biotransformed to the principle
metabolite: dihydroartemisinin (DHA). Both the parent drug and metabolite are
active against the malaria parasite. The plasma half-life of these products
(both parent-drug and metabolite) is relatively short compared with other
antimalarial agents and frequent dosing has been used. Following a single rectal dose, artesunate (AS) and dihydroartemisinin
(DHA) are detectable in plasma beginning about 30 minutes after dosing in most
adult and pediatric patients.
Concentrations of artesunate and DHA become undetectable in plasma after
about 5 hours and 12 hours, respectively.
Despite their efficacy in reducing parasite counts, these products have been associated with high rates of recrudescence. To address this, they are often used in combination with other antimalarial agents, and are given repeatedly over several days.
Literature reports indicate that certain artemisinins have been associated with neuropathological changes in a variety of animal species (mice, rats, dogs, and rhesus monkeys). These changes include chromatolysis and gliosis in the brainstem nuclei associated with auditory, vestibular and muscle-control functions. They have been most strongly associated with the oil-based artemisinin derivatives, artemether and arteether.
Neurological abnormalities have not been reported in human subjects. However, the assessment of neurological changes in patients who present with acute malaria is difficult, since the disease itself may result in baseline neurological abnormalities and rarely in neurological sequelae. Further, the assessment of neurological symptoms in children may be difficult.
Drugs approved by the US Food and Drug Administration (FDA) for the treatment of malaria cause by P. falciparum include chloroquine (oral, IV or IM), fansidar (oral), mefloquine (oral), quinidine (IV or oral), quinine (IV IM or oral), malarone (oral) and halofantrine (oral). Since all these alternatives require oral or parenteral administration, none is suitable for patients in the bush who are unable to take orally, and who have no immediate access to trained medical personnel.
Proposed indication:
“Artesunate Rectal Capsules is indicated for the initial management of
acute malaria in patients who cannot take medication by mouth and for whom
parenteral treatment is not available.
Warning: Artesunate rectal capsules are not intended for the initial
treatment of malaria if it is possible to provide immedidate treatment of the
patient with orally or parenterally (intravenous or intramuscular) administered
antimalarials.
Precautions: Artesunate rectal capsules have not been evaluated as sole
therapy for malaria; consequently all patient who are initially treated with
artesunate rectal capsules should be promptly referred and evaluated at the
nearest health care facility able to provide a full curative course of
treatment for malaria.
General: Artesunate rectal capsules are indicated only for use in initial
management of acute non per-os P. falciparum malaria and MUST be
supplemented and/or followed by effective oral or parenteral drug therapy for
malaria as soon as possible.”
Challenge to develop appropriate studies:
Since rectal artesunate is to be used as emergency treatment for malaria when no alternatives are available, the practical question is whether the emergency use of a single dose of rectal artesunate is more effective than no treatment in reducing malaria morbidity and mortality.
Given the high mortality from untreated malaria and the dangers of delaying effective therapy, treatment cannot be ethically withheld for the first 24 hours. For these reasons, the product has been studied in trials employing active comparators. In these studies, provisions are made for the “rescue” of patients showing an unsatisfactory clinical or parasitological response. While these studies do not directly address the advantages of rectal artesunate over no treatment, they give a relative idea of efficacy versus the “standard of care”.
Approach:
Three pivotal studies used a single dose of rectal artesunate alone for the first 24 hours and compared this with standard therapy for 24 hours. This was followed by a definitive or “consolidation” regimen in both treatment arms.
Shortcomings in reflecting projected use:
· The diagnosis of malaria was confirmed in study participants. This would not be the case in the bush where malaria might be confused with meningitis, typhoid and a host of other febrile illnesses.
· The studies provided ancillary treatment: fluid, transfusions, antipyretics, and anticonvulsants. These would not be available in the bush.
· Drug administration was well supervised. In the bush, supervision would depend upon family members.
· Patients in the field might get a false sense of security after rectal treatment and fail to present for definitive therapy.
Design problems:
Study populations were drawn from communities where malaria was prevalent and were likely to show various degrees of malarial immunity.
Difficulties were apparent in attempts to standardize the severity of disease.
· In some studies the inability to take orally was taken as a sign of severity.
· In others impairment of consciousness was taken as a sign of severity.
· Baseline parasitemia varied from study to study.
· Where malaria was more prevalent, subjects were likely to have some immunity and to tolerate higher parasitemias with milder clinical manifestations.
Mindful of the serious consequences if treatment failed, the applicant allowed subjects in the rectal artesunate arm of the studies to be rescued with standard therapy if the parasite count failed to reach 60% of baseline by 12 hours. (Rescue of subjects in the comparator arm was permitted in 2 of the 3 pivotal studies.)
Since the efficacy of AS is being tested for 24 hours, the evaluation of patients rescued before this time is difficult.
- Evaluating them as successes effectively ignores the contribution of the rescue therapy.
- Evaluating them as failures discounts the possibility that in some patients, the parasitological response may be a little slower
- Excluding them from the analysis relegates the efficacy analysis to “successes amongst the successes”
The problem of endpoints:
Is parasitemia an appropriate surrogate for clinical response?
Responses in peripheral parasitemia are an useful indication of the activity of antimalarial drugs for several reasons:
· Since untreated patients generally demonstrate rising levels of parasitemia with time, decreases in parasitemia are a persuasive reflection of drug activity.
· Parasite counts provide a quantifiable measurement of drug activity allowing a measurable comparison of different treatment regimens.
· The parasite count is a simple and robust test that is easy to perform and easy to interpret.
However, responses in peripheral parasitemia may not always reflect the clinical outcome and the following pitfalls should be borne in mind:
· Sequestration of parasites in the spleen and other organs has been described and may account for the morbidity and mortality in some patients with low peripheral parasite counts. Thus resolution of peripheral parasitemia may not always reflect the clinical outcome.
· Potentially fatal complications of malaria, such as renal failure or pulmonary edema, may supervene even when the peripheral parasite count is very low.
· The degree of parasitemia correlates to some extent with severity of disease. In non-immune patients, parasitemias affecting more than 5% of peripheral erythrocytes are taken to indicate severe malaria according to WHO (Trans Roy Soc Trop Med Hyg 1990, 84 Supple 2 1-65). However the parasite count may not always reflect malaria severity, as semi-immune patients may tolerate this degree of parasitemia with minimal symptoms.
Issues in selecting appropriate endpoints to reflect drug efficacy
· The rate of parasite clearance indicates one aspect of drug performance that may correlate with efficacy. However, to date, no clinical advantage (in terms of morbidity or mortality) has been identified using artemisinins (which clear parasites very rapidly) compared to quinine (which clears parasites more slowly).
· The median rate of parasite clearance in a group of patients may also fail to reflect the percentage of outlying individuals who respond poorly.
· Clinical failures may occur despite disappearance of parasites from peripheral blood.
· An evaluation several weeks after presentation generally should reflect the initial outcome of treatment but is complicated by losses to follow up, new infections and recrudescent infection. In the clinical trials reflected in this NDA, the long-term outcome depends substantially on the efficacy of the drugs used following the initial dose of rectal artesunate.
· The relative morbidity and mortality of initial attacks of malaria versus recrudescent attacks after therapy in patients without access to medical care is not clear.
Ultimately, the evaluation of efficacy depends on the aggregate of clinical and parasitological responses evaluated over several weeks.
Safety:
Safety may be difficult to assess in sick patients with malaria. Neurological symptoms are difficult to determine in young children. Malaria itself may produce neurological symptoms. Occasionally these may be severe and long lasting.
Based on the known toxicity profile of the artemisinin compounds, the applicant agreed to conduct a nonclinical study to determine the neurotoxic potential of artesunate. The study was to determine the dose, duration of dosing, and possibly the total systemic exposure to artesunate needed to produce unacceptable neurotoxicity in an appropriate animal model. A subacute repeat-dose oral and intravenous toxicity study in rats was conducted to address these issues. In the original study design, rat dosing groups (16 rats/group) received oral doses of 33, 75, or 150 mg/kg/day or intravenous doses of 10 mg/kg (3 times daily), or 30 mg/kg (3 times daily), for seven days followed by either necropsy (8 rats/group) or a 14-day recovery (8 rats/group). During the study, mortality, weight loss, hypoactivity, decreased food consumption and perianal/urogenital staining were observed in the 75 and 150 mg/kg/day oral dose groups and 90 mg/kg/day intravenous group as early as Day 3.
Of particular concern was the failure to conduct either behavioral assessments or specific neuropathologic examinations needed to determine the parameters of interest (dose and duration of dosing needed to produce neurotoxicity). Especially troubling was the fact that rats died on study (1/16 and 2/16 receiving 75 and 150 mg/kg, respectively, after as little as three days of dosing), or were sacrificed early (90 mg/kg/day intravenous group, day 3) because of poor health. The cause of death was not determined, leaving open the possibility that the animals died due to neurotoxic effects (or possibly other toxicities). To further compound the problem, treatment was discontinued in the surviving rats in these dose groups, limiting actual exposure to artesunate. Necropsy results on these animals cannot be taken to indicate lack of neurotoxicity since these animals received much less drug than originally planned and were sacrificed as long as 10 days after the final oral doses. (In fact, in rats surviving until scheduled sacrifice, hepatic toxicity was noted in all treatment groups, consisting of centrilobular hepatocyte hypertrophy, sinusoidal inflammation cells, single cell necrosis, diffuse hepatocyte vacuolation and periportal vacuolation. Hepatic effects were not observed in recovery group animals.)
Histopathologic
sectioning of CNS tissues obtained from animals sacrificed at the end of the
study was of uncertain precision. The
study report does not specify that brain loci
known to be targets of artemisinin-induced neuronal damage were
examined; it is thus possible that lesions were present but not observed. Studies have been published in which the
neurotoxicity of artemisinins, including artesunate, was assessed in rodents
using appropriate methods (neurohistology and functional assays); these
published reports could have been used by the applicant to design an
appropriate study to address the issues of concern (Kamchonwongpaisan et al,
1996; Genovese et al, 1998). These
studies, as well as other published papers, can be taken to indicate that
artesunate is less neurotoxic than
other artemisinin derivatives (using both neuropathology as well as functional
assays such as drug effect on balance and gait). However, in one published study (Nontprasert et al, 2000), artesunate was given
to mice by daily oral gavage for 28 consecutive days followed by a 120-day
recovery period; neurotoxic effects were observed at exposures similar to
clinical doses
A further
problem in assessing the findings in the subacute oral toxicity study in rats
is that an inappropriate method of comparing rodent to human doses was
used. Dose comparisons should be made based on relative body surface
areas, not body weights. Using
comparative body surface areas for calculations of dose equivalents, the safety
margin between the proposed human dose and doses that produced adverse effects
in rats (poor condition and death) is not of the same magnitude as reported by
the applicant (see the table below). Based on this method, the following human
equivalent doses were used in the subacute oral toxicity study in rats:
Table 1: Dose comparison based on body surface area differences
Rat dose (mg/kg), 7-day study, oral dose |
Human equivalent dose (mg/kg) |
Multiple of human dose |
Toxicity |
Mortality |
33 |
5.5 |
0.55 |
Liver (?) |
|
75 |
12.5 |
1.25 |
Liver (?) |
1/16 |
150 |
25 |
2.5 |
Liver (?) |
2/16 |
Determination
of systemic drug exposures (Cmax, AUC) at which toxicities were
observed in animals is the most useful method for establishing safe doses in
humans. However, the ability to
compare systemic artesunate exposure in nonclinical studies conducted by the
applicant is limited by the quality of the available data. In a single dose toxicity study in rats, Cmax
of 442.3 ng/ml at 150 mg/kg , p.o., were calculated with AUC of 520
ng•hr/ml. If linear pharmacokinetics
are assumed an extrapolation for the 75 mg/kg p.o. dose in rats provides a Cmax
of about 220 ng/ml and AUC of 250 ng•hr/ml.
These exposures, at which deaths occurred, compare to clinical exposures
following a rectal dose of 10 mg/kg producing a Cmax of about 1100
ng/ml and AUC of 4300 ng•hr/ml. Unfortunately,
pharmacokinetic data supplied by the applicant are not reliable based on
careful review. The limited
cumulative dose exposure from the 7-day rat study in which the dosing duration
was shortened does not permit a valid toxicity comparison relevant to human
exposure. Therefore, safe doses can only be determined by calculation using relative
body surface areas.
Additional non-GLP studies performed in the People’s Republic of China during the 1980’s were included in support of the application. The studies are of uncertain value since these could not be audited and the translations from Chinese are of poor quality. However, adverse effects, such as hepatotoxicity and hematotoxicity, were reported in dogs and rats given both acute and repeated oral and intravenous doses of artesunate.
In summary, the apparent major safety concern for artesunate, neurotoxicity, remains inadequately characterized. The nonclinical study designed to assess neurotoxic potential was not performed in a way that provides useful data. Published studies provide some relevant information for determining safety. While artesunate appears to have less neurotoxic potential compared to other artemisinins, mice exhibited neurotoxicity after prolonged exposure. The issue of an unacceptably toxic dose has not been addressed and neurotoxicity must be considered a risk following multiple-dose exposure in humans. The possibility that artesunate also produces hepatotoxicity has not been adequately addressed (this was an unanticipated finding.)
Biology of the parasite:
Over 100 species of Plasmodium have been shown to cause malaria in a wide variety of
vertebrate hosts. The four species
known to infect man are P. falciparum,
P. vivax, P. malaria, and P. ovale. The life cycle of the malaria parasite (Plasmodium) is divided between 2 hosts:
mosquitoes (as a vector) and vertebrates (Figure 1). Infection in humans is initiated by the bite of infected
mosquitoes and sporozoites are inoculated into the blood stream. Within
2 hours, the sporozoites migrate to the liver and penetrate the hepatocytes. After 1 to 2 weeks, the sporozoites
undergo nuclear division to produce thousands of merozoites that are released
by the rupture of the host cell. This phase
of the life cycle of Plasmodium is
called exoerythrocytic or liver schizogonic phase. The merozoites invade the erythrocytes and
progress through a series of developmental forms into mature erythrocytic
schizonts. Each merozoite matures into
a schizont, undergoes asexual multiplication, and forms 24 merozoites. The red blood cells rupture and the
merozoites invade other erythrocytes.
This part of the life cycle is called the erythrocytic phase and takes about 24 to 72 hours. Fever is associated with the rupture of
infected red blood cells. Severe or fatal complications can occur at any time
and are related to blockage of blood vessels in the internal organs such as
brain, spleen, bone marrow, etc. Some
merozoites mature into male and female gametocytes within the
erythrocytes. The maturation of these
gametes occurs once the infected blood is ingested by the mosquitoes. The gametes undergo fertilization within the
vector and form a zygote. This is
followed by the elongation of a zygote to form an ookinete in about 12 to 48
hours. The ookinetes invade the stomach
of the mosquito and develop into oocysts.
The oocyst enlarges forming over 10,000 sporozoites (in about a week
after the formation of the oocyst). The
sporozoites released by the rupture of the oocyst migrate to the salivary
glands of the mosquitoes and are inoculated into humans the next time the
mosquito feeds (i.e., during a blood meal).
In patients with P. falciparum infection,
recurrence is generally thought to be due to recrudescence, which is caused by residual erythrocytic forms;
whereas in P. vivax and P. ovale relapse of an infection is considered to be due to dormant
parasites (hypnozoites) in the liver
which undergo development and release merozoites into circulation.
Mechanism of action:
Artesunate is a water soluble derivative of artemisinin, an antimalarial compound isolated from the Chinese herb Qinghao (Artemisia annua). Artesunate is rapidly metabolized to dihydroartemisinin (DHA) in the body. Chemically, artesunate, and its active metabolite, DHA, are sesquiterpene lactones with a trioxane ring containing a peroxide bridge. The peroxide bridge appears to be essential for the antimalarial activity of artesunate. Structure-activity relationship studies show that the deoxy derivative of DHA (that lack the peroxide bridge) was 277-fold less active than DHA. The activity of deoxyartesunate was not measured. Deoxy derivatives of other artemisinin analogs were 10- to 1000-fold less active compared to the parent compounds. Artesunate increases superoxide anion production and lipid peroxidation in falciparum-infected erythrocytes in vitro. However, artesunate does not suppress the activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione reductase, and glutathione peroxidase) in infected or uninfected erythrocytes.
Erythrocytes infected with the ring or trophozoite forms in vitro accumulate 100- and 180- fold higher concentrations of DHA (12 nM i.e., 3.40 ng/ml), respectively, compared to uninfected erythrocytes. These experiments were performed in a medium containing 10% human serum. The relevance of these findings to the uptake in vivo is unclear. The precise mechanism by which artesunate exhibits antiplasmodial activity is not understood.
Activity in vitro:
Artesunate and DHA exhibit activity against the erythrocytic stages of P. falciparum, which includes laboratory strains and several clinical isolates from different geographical areas. The antiparasitic activity was measured by incorporation of 3H-hypoxanthine or by microscopic observations. A majority of these studies were done by incubating the asynchronous parasites with the drug for 24 to 48 hours. The results expressed as 50% inhibitory concentration (IC50) show the artesunate and DHA IC50 values against the laboratory strains or clinical isolates to be < 7 and < 24 ng/ml, respectively (Tables 2 and 3).
Table 2: In vitro activity against the laboratory strains of P. falciparum.
Strain |
Resistance |
Artesunate IC50 (ng/ml) |
DHA IC50 (ng/ml) |
FCC-1/HN |
Chloroquine
sensitive |
1.04 |
ND |
D10 |
Chloroquine-sensitive |
2.14 (0.12 - 2.46)* |
(0.28 - 1.15)* |
3D7 |
Chloroquine-sensitive |
(0.12 - 0.20)* |
(0.28 - 1.15)* |
RSA11 |
Chloroquine-resistant |
1.32 (1.01 - 1.63)* |
ND |
FCD-3 |
Chloroquine-resistant |
ND |
2.70 |
K1 |
Chloroquine-resistant |
5.60 (4.70 - 6.90)* 4.60 (4.00 - 5.50)* |
3.60 (2.30 - 3.80)* 3.10 (2.90 - 3.60)* |
W2/
Indochina |
Chloroquine-resistant
and Mefloquine-sensitive |
0.64 |
0.68 |
D6/Sierra
Leone |
Chloroquine-sensitive
and Mefloquine-resistant |
0.84 |
0.70 |
*Represents the results of multiple testing. ND = not done.
Table 3: In vitro activity against P. falciparum isolates from different geographical regions.
Region |
N |
Resistance |
Artesunate Mean (range) IC50 ng/ml |
DHA Mean (range) IC50 ng/ml |
Reference |
Philippines |
24 |
Chloroquine and amodiaquine |
0.35 (0.12 - 3.15) |
ND |
Bustos
et al., 1994 |
Vietnam |
10 |
Chloroquine, amodiaquine,
mefloquine, and sulfadoxine/pyrimethamine |
1.24 (1.13 - 1.36) |
0.92 (0.84 - 1.01) |
Wongsrichanalani
et al., 1997 |
Vietnam
and China |
4 |
Chloroquine |
NA (0.08 - 0.24) |
NA (0.23 - 0.85) |
Skinner
et al., 1997 |
China-Mynamar |
51 |
Chloroquine |
2.30 (NA) |
3.70 - 3.98 (NA)a |
Yang
et al., 1997 |
China-LaoPDR |
42 |
Chloroquine |
1.92 - 2.69 (NA) |
1.14 - 1.42 (NA) |
Yang
et al., 1997 |
Thailand |
86 |
Chloroquine and mefloquine |
NA (0.36 - 1.65) |
NA (0.34 - 0.98)b |
Wongsrichanalani
et al., 1999 |
Africa |
79 |
Chloroquine |
ND |
NA (0.25 - 0.43) |
Le
Bras et al., 1998 |
Thai-Burmese
Border |
178 72 |
Chloroquine, amodiaquine,
sulfadoxine-pyrimethamine and mefloquine |
1.62
(0.19 - 13.30)c,e 2.35
(0.34 - 23.40)d,g |
1.22 ( 0.15 - 6.60)c,f 1.43 (0.24 - 8.10)d,h |
Brockman et al., 2000 |
IC50 Range 0.08 - 23.4 0.15 - 8.10 (ng/ml) (n = 467) (n = 322) |
NA = Not available;
ND = not done;
a14 isolates were tested;
b 45 isolates were tested;
c primary infection isolates
d recrudescent isolates [after treatment with mefloquine (25 mg/kg)
+ artesunate (12 mg/kg x 3 days)]
e 95% CI (1.4 - 1.8 ng/ml)
f 84 isolates, 95% CI (1.9 -
2.9 ng/ml)
g 95% CI (1.0 - 1.5 ng/ml)
h 44 isolates, 95% CI (1.1 -
1.8 ng/ml)
Studies using synchronous culture show a rapid inhibition of the ring, trophozoites, and schizont forms of P. falciparum within 2 hours of exposure to DHA at a concentration equivalent to the IC90 value (Figure 2).
Figure 2: Stage-specific activities of quinine,
artemisinin, artemether, and DHA on culture-adapted parasites of Plasmodium falciparum. Synchronized
cultures of rings (0 h; ·), trophozoites (20-24 h; s) and schizonts (36 h; n) were exposed to the IC90
concentration (not specified) of each
drug up to 10 hours. The data are
presented as percentage growth inhibition ± S.D. with time of drug exposure for
the 3 asexual stages compared with untreated controls. The IC50
values were as shown below:
Drug IC50 values (M)
_____________________________
DHA 0.8
- 3.0 x 10-9
(0.28
- 0.85 ng/ml)
Artemisinin 2.0 - 30.0 x 10-9
Artemether 7.0
- 30.0 x 10-12
Quinine 3.0
- 10.0 x 10-8
(Skinner et al., 1996)
Studies using predominantly gametocytes in culture showed that the DHA IC50 value to be 6.6 ng/ml. Time to gametocyte kill was not measured.
The activity of artesunate may vary with the source of erythrocytes. For example, artesunate was 3- to 10-fold less active against the K1 strain of P. falciparum using genetically variant erythrocytes from patients with a-thalassemia (hemoglobin Hb[H] and Constant spring, HbCS) than normal RBCs. The activity of chloroquine was similarly altered whereas that of pyrimethamine was not altered by the source of the erythrocytes.
No studies were done to demonstrate the in vitro activity of artesunate or DHA against the hepatic stage of the Plasmodium species.
Activity in vivo:
The activity of artesunate and DHA was measured against the erythrocytic forms of P. falciparum, P. berghei, P. knowlesi, and P. coatneyi in mice or monkeys. In a preliminary study conducted in immunocompromised mice infected with the T24 strain (chloroquine and quinine resistant) of P. falciparum, a complete clearance of parasite from the blood was observed on Day 2 of treatment with DHA (50 mg/kg for 2 days) by the oral route. Microscopic observations at 24 hours showed predominantly pycnotic forms (76%), some altered trophozoites (10%), few trophozoites (1%), and schizonts (3%). At 48 hours, only pycnotic forms were observed. Chloroquine and quinine were not effective in clearing the parasitemia in mice infected with the T24 strain. Treatment with chloroquine induced minimal alterations in morphology (11 - 16% pycnotic forms). However, against a chloroquine sensitive strain (NF54) morphological changes after treatment with chloroquine were similar to that of DHA against the chloroquine-resistant strain. The activity of artesunate was not measured.
In mice infected with P. berghei (173N strain) and treated with intravenous artesunate or chloroquine, a 50% and 90% reduction in parasitemia was observed by 18 to 24 hours, and 24 to 30 hours, respectively. Recrudescence was observed on Day 28 in mice treated with artesunate (110 mg/kg) for 5 days by the intravenous route. However, chloroquine (14.9 mg/kg for 5 days) completely cured the mice on Day 28. In another study, mice infected with another strain of P. berghei (ANKA strain) showed complete cure on Day 60 after intramuscular treatment with ³ 56 mg/kg artesunate. Complete clearance of the parasitemia was observed within 2 days of treatment. Similar observations were made with DHA. The variation in the activity of artesunate in the different studies may be due to the different strains of P. berghei used for infection, the route of drug administration or severity of infection.
In monkeys infected with P. knowlesi, the intravenous administration of artesunate (10 mg/kg for 7 days) reduced the parasitemia by 90% at 13 hours. The parasite clearance time (PCT) was 42 hours and all 3 monkeys remained negative for 28 days of observation. However, at the lower dose (3.16 mg/kg), although the PCT was 40 hours, 1/3 monkeys showed recrudescence on Day 15. At a higher dose (31.6 mg/kg), the mean parasite clearance time was 56 hours and no recrudescence was observed. Quinine at 10 mg/kg dose was effective in reducing the parasitemia by 50% in 3.3 hours, however, a 90% reduction of parasitemia was not attained. At a higher dose (31.6 mg/kg), the mean time to parasite clearance was 104 hours and recrudescence was observed 2 to 10 days after parasite clearance.
In another study, normal and splenectomized monkeys infected with P. coatneyi were treated with artesunate. The clearance of parasitemia was slower in splenectomized animals compared to normal controls. The reduction in parasitemia at 24 hours in the splenectomized and non-splenectomized animals was 86% and 99%, respectively. Infected erythrocytes showed ultrastructural changes such as enlargement of food vacuoles and ribosomal clumping 4 hours after administration of artesunate.
The activity of artesunate against hepatic stages of the Plasmodium species was not examined.
Resistance:
A potential for resistance development by Plasmodium species to artesunate was examined in vitro and in vivo. In a preliminary study, the erythrocytic forms of the FCR3 strain of P. falciparum were passaged by exposure to increasing concentrations of artesunate (starting with 4 ng/ml) for 48 hours each, followed by growth in drug-free medium for 18 days (equivalent to 9 life cycles). The artesunate IC50 value increased by 3-fold after 6 to 7 passages over a period of 130 days. Such an effect was reversible when the parasites were grown in drug free medium for 5 weeks.
Studies in vivo show that serial passage of the N strain of P. berghei in mice treated with escalating doses of artesunate for 4 days each, increased the 90% effective dose (ED90) by about 29-fold after 21 passages (85 days). The effect was reversible after discontinuation of therapy. However, the clinical significance of these observations is unknown.
In patients with severe or moderate malaria, treatment with a single dose of rectal artesunate decreased the parasite count by > 90% in 24 hours. In patients treated with multiple doses of artesunate (oral, rectal or IV) the parasite clearance time was 16 to 56 hours. However, recrudescence was reported on Days 10 to 28 after discontinuation of therapy. In the absence of genotyping and phenotyping it is unclear whether the recrudescence is due to resistance. Also, the presence of dormant parasites cannot be ruled out.
Cross-resistance:
P. falciparum strains with chloroquine resistance (IC50 > 100 nM) and mefloquine resistance (> 20 nM) were susceptible to artesunate in vitro. However, a positive correlation was observed between the in vitro activity of artesunate and those of halofantrine, mefloquine, quinine, or atovaquone, suggesting cross-resistance. The clinical significance of the in vitro observations is unclear.
Although no correlation was observed between the in vitro activity of artesunate and
chloroquine against P. falciparum, a
16 - 17 fold higher concentration of artesunate was required to suppress 90% of
asexual forms of P. berghei
chloroquine-resistant RC strain than the chloroquine-sensitive N strain in
mice, suggesting likelihood of cross-resistance. However, in another study DHA
was effective in clearing parasitemia in mice infected with a
chloroquine-resistant T24 strain of P.
falciparum.
In clinical studies, artesunate was effective in the treatment of P. falciparum infections from regions known to be resistant to chloroquine.
Drug combination:
The in vitro activity of artesunate in combination with other drugs against P. falciparum was measured. A combination of artesunate with mefloquine or quinine was synergistic against P. falciparum. However, a combination of artesunate with pyrimethamine was antagonistic. The combination of artesunate with chloroquine varied from additive to anatgonistic against the different P. falciparum strains tested. The oxidant drugs (miconazole and doxorubicin) also show a synergistic effect in combination with artesunate. The in vivo activity of artesunate in combination with other antimalarials was not examined.
The activity of artemisinin in combination with other antimalarial drugs against P. falciparum was measured in vitro and against P. berghei in vivo. A combination of artemisinin with mefloquine was synergistic whereas that with pyrimethamine was antagonistic in vitro and in vivo. A combination of artemisinin with other antimalarials (sulfadiazine, sulfadoxine, sulfadoxine-pyrimethamine, cycloguanil, and dapsone) was also shown to be antagonistic in vivo.
An overview of the studies supporting clinical efficacy is provided below.
Table 4: Synopsis of data supporting the efficacy of rectal artesunate in NDA 21-242
Study number |
Clinical Site Location |
# Allocated to Rectal Artesunate |
# Allocated to Comparator |
Type of Patient |
003 |
Thailand |
24 |
24 |
Adults |
004 |
Ghana |
24 |
12 |
Children |
005 |
Thailand |
46 |
17 |
Children |
006 |
Malawi |
87 |
22 |
Children |
007 |
South Africa |
27 |
8 |
Adults |
014 |
Thailand |
69 |
0 |
Adults |
009 |
(literature) |
|
|
|
010 |
(literature) |
|
|
|
011 |
(literature) |
|
|
|
Studies in patients with clinical malaria
Six studies were performed on patients with clinical malaria.
Three comparative studies (005, 006, and 007) employed the projected dose of rectal artesunate given alone for the first 24 hours of therapy in the experimental arm. These were regarded as pivotal studies.
A bioequivalence study (Thailand 014) comparing 3 formulations of rectal artesunate in the projected dosing regimen provided further non-comparative data on the safety and efficacy of rectal artesunate, when used as proposed.
Two further studies (Thailand 003, Ghana 004) employed regimens for rectal artesunate that differed either in dosage or duration from the projected use and provided supportive information.
Data from three older published studies (009, 010, and 011) were reanalyzed by the applicant and presented as supportive data. The dose of rectal artesunate in each of these studies was twice the proposed clinical dose. As such, these studies did not support the efficacy of the proposed dose, although the information provided some evidence of safety.
FDA considered three studies, performed in Thailand, Malawi and South Africa, as pivotal in supporting this indication. In each of these studies the experimental arm involved treatment with rectal artesunate 10mg/kg as a single dose for the first 24 hours, followed by one of several follow-up or “consolidation” antimalarial regimens. All three studies were randomized, comparative and unblinded.
The studies differed in several ways from the envisaged use of the product. In all three studies, patients were admitted to hospital. The diagnosis of malaria was confirmed on smear, and the progress of parasitemia was monitored. Permitted ancillary treatment including transfusions, parenteral fluids, anticonvulsants, antipyretics, and glucose given at the clinicians’ discretion.
The study designs are compared below
Table 5: Drug regimens used in pivotal studies
|
Location (Study No) |
||
|
Thailand (005) |
Malawi (006) |
South Africa (007) |
Experimental arm |
Rectal AS (10mg/kg) single dose |
Rectal AS (10mg/kg) single dose |
Rectal AS (10mg/kg) single dose |
Comparator |
Oral AS (4 mg/kg) single dose |
Quinine 10mg/kg IM or IV at 0, 4 hrs then 12 hourly till oral treatment tolerated |
Quinine 10mg/kg IM or IV at 0, 4 and 12hrs |
Consolidation regimen |
24 hrs: Oral AS (2mg/kg) 48 hrs: Oral AS (2mg/kg) + MQ (15mg/kg) 72 hrs: Oral AS (1mg/kg) + MQ (10mg/kg) Daily for 6 more days: Oral AS (1mg/kg) |
24 hrs: Oral SP* (25mg/kg SDX) (or “standard dose” parenteral quinine if unable to take orally) SP given at 24 hours in experimental arm SP given after a minimum of 2 doses of quinine in comparator arm |
24 hrs: Oral SP (3 tablets) single dose (or IM quinine 10mg/kg if unable to take orally) |
*SP - sulfadoxine-pyrimethamine
[The
raw pharmacokinetic data from Study 07 have not been submitted and therefore a
detailed review has not been performed to verify the pharmacokinetic parameters
obtained in this study.]
Comment on treatment regimens:
The final treatment
outcome, several weeks after completing therapy, is a reflection of the
efficacy of the total treatment regimen. Recurrences of parasitemia shortly
after finishing treatment may reflect a treatment regimen that is inadequate in
terms of dose or duration, or infection with a parasite that has some degree of
resistance to the drug.
SP is a long-acting
agent and the recommended regimen for the treatment of acute malaria in adults
is a single dose of 3 tablets. (In children, an appropriate single dose is
calculated on a mg/kg basis.) Malaria that is resistant to SP is common, and
may vary by geographic region. Thus, studies performed in different locations
may show different long-term outcomes when SP is used. In parts of Africa,
resistance to SP may be present in up to 60% of cases.
Mefloquine is a
long-acting agent and the recommended regimen for the treatment of acute malaria
in adults is a single dose of 1250mg. Mefloquine resistance appears less
prevalent than SP resistance. Mefloquine has been used in combinations with
artemisinin derivatives for the clinical management of malaria in parts of
Thailand where multidrug resistant P
falciparum is prevalent.
Quinine sulphate is used
to treat malaria in adults at a dose of 600 mg tid for 7 days, often in
combination with doxycycline. Shorter courses are prone to result in
recrudescences.
The entry criteria aimed to capture “moderately severe” malaria.
Table 6: Inclusion and exclusion criteria for pivotal studies
|
Location (Study No.) |
||
|
Thailand (005) |
Malawi (006) |
South Africa (007) |
Age |
6 months-15 years |
1 – 10 years |
16 years – 65 years |
Eligible parasitemia |
>4% (200,000/:l) |
>0.4% (<20,000/:l) |
- |
Clinical eligibility |
- |
Unable to eat or drink or Impaired consciousness |
Unable to eat or drink |
Exclusion |
Diarrhea |
Diarrhea |
Diarrhea |
Unable to eat or drink |
- |
- |
|
Previous antimalarial in past 24 hrs |
Previous antimalarial in past 24 hours |
Previous antimalarial in past 24 hours |
|
Severe malaria: · Acidotic · Hct < 15% · Jaundice · Bleeding · Shock · Decreased consciousness |
Severe malaria: · Deep breathing · Hct < 18% · Jaundice · Bleeding · Shock · Stupor or coma · Convulsions |
Severe malaria*: · Respiratory distress · Jaundice · Bleeding · Shock · Coma · >1 Convulsion · Renal failure · Hypoglycemia · Lactate < 5 mmol/l |
|
Parasitemia >20% |
Parasitemia >10% |
Parasitemia >10% |
* Two additional arms were originally included in this study to incorporate patients with the features of severe malaria. Since the treatment in all these patients was to be quinine with or without artesunate, the results in these arms were not considered pivotal to this application. During the study, it was determined that facilities were inadequate for such sick patients and these arms were discontinued after recruiting a total of 11 patients. Among the 11 patients there were 3 deaths. Ultimately all 3 deaths were attributed to the complications of severe malaria.
Results
Characteristics of the study populations are described below:
(In each row of the table, results are listed for the rectal artesunate-arm above and the comparator-arm below)
Table 7: Baseline characteristics of patients in pivotal studies
|
Location (Study No.) |
||
|
Thailand (005) |
Malawi (006) |
South Africa (007) |
Number of patients Artesunate Comparator |
46 17 |
87 22 |
27 8 |
Mean Age Artesunate Comparator |
7 years 7 years |
4 ½ years 4 years |
29 yrs 25 yrs |
% Males |
63.5% |
61.5% |
51% |
Entry parasitemia Artesunate Comparator |
Geom mean 260,600 409,900 |
Geom mean 180,000 217,000 |
Median 55,000 101,000 |
Platelet count Artesunate Comparator |
Median 85,000 129,000 |
Geom mean 74,500 67,000 |
Mean 75,000 72,500 |
In all three studies, the patient demographics, the severity of disease, and clinical laboratory results at baseline were balanced between the treatment arms.
Protocol defined criteria for “rescue” with other antimalarial agents included:
· A parasite density $60% of the admission parasite density after 12 hours.
· Clinical deterioration with the development of features of severe malaria, repeated convulsions or coma.
In each study, “rescue” was permitted as shown:
Table 8: Provisions for rescue therapy in pivotal studies
Thailand (005) |
Malawi (006) |
South Africa (007) |
Rescue in both arms |
Rescue only in rectal artesunate arm |
Rescue in both arms |
Once a patient was rescued with a non-study drug, any clinical or parasitological finding subsequent to rescue could not be clearly attributed to the study drug. The FDA regarded rescued patients as clinical failures.
It is recognized that this approach erred on the side of stringency since many patients treated for malaria do not reach a parasite density <60% of baseline at 12 hours, despite which they proceed to recover clinically.
The applicant used the fractional reduction in parasite counts at 12 and 24 hours as the primary basis for the determination of comparative drug efficacy. In this analysis, clinical and parasitological failures who received non study-therapy were treated as “withdrawals”. Clinical failures and those patients receiving rescue therapy were separately presented.
The FDA defined the following clinical and parasitological endpoints to incorporate data from all patients randomized to treatment, including those who were rescued because of clinical or parasitological deterioration.
Table 9: FDA defined endpoints
24-hour clinical success |
All treated patients: · who were evaluated after 24 hours on study drug ·
who had not received rescue therapy or alternative
antimalarial therapy · who neither died nor deteriorated clinically since the baseline evaluation |
24-hour parasitological success |
All 24-hour clinical successes whose 24 hour parasite count was #10% of the baseline count* |
28-day recrudescence/ re-infection |
Any patient who received study drug and was found to have a recurrence of parasitemia between the time that therapy was stopped and day 28. |
* This composite endpoint was created since it represented the outcome just before administration of the follow-up regimen and was considered to reflect the activity of rectal artesunate when used as proposed while taking into account prior rescue therapy. Since parasite clearance >90% of baseline was a parameter that the applicant determined in all studies, and was a clear indicator of a favorable treatment response, it provided a suitable representation of the parasitological component in the 24-hour efficacy assessment.
Study-related events with an impact on the clinical results are described in the table below.
Table 10: Study related events with an impact on clinical results for pivotal studies
(In each row of the table, results are listed for the rectal artesunate-arm above and the comparator-arm below)
|
Location (Study No.) |
||
|
Thailand (005) |
Malawi (006) |
South Africa (007) |
Number of patients Artesunate Comparator |
46 17 |
87 22 |
27 8 |
Exclusions Artesunate Comparator |
5 3 |
3 0 |
1 1 |
Rescued for 12 hour parasitemia $60% of baseline Artesunate Comparator |
7 4 |
3 0 ( no provision for rescue) |
1 2 |
Clinical deterioration Artesunate Comparator |
1 0 |
4 0 |
0 0 |
Death Artesunate Comparator |
1 0 |
0 0 |
0 0 |
Other failures Artesunate Comparator |
1 (expelled supps) N/A |
1 N/A |
0 0 |
As detailed above, there was one death in a patient in study 005. The description of this case is provided below.
Case report of death on study
This
3-year-old boy was admitted following a 24-hour history of fever. He was able
to sit, stand, drink and eat unaided. Admission parasite count was 40/1000 RBC
(4%) HCT was 34% WBC 15.3, and platelet count 211K. Glucose was 3.3mmol/L. The
child was given 3 x 50mg rectal capsules.
As the child was not drinking and IV infusion was started at 20 drops per minute. It was later noted that 650cc were accidentally infused over 77 minutes. Despite this, the child seemed well and was eating cake. Two and a half hours after starting therapy the child vomited and died suddenly. A parasite count shortly before death was 65/500 WBC. (Since the RBC was not given, only an approximate comparison of this count and the admission count was possible. The follow up count (~0.01%) was substantially lower than the admission count. It was found that sodium levels had fallen from 139 to 117, potassium levels from 3.5 to 2.5 and albumin from 3.8 to 3.2 over 2 hours. The consensus of the investigators and expert consultants was that the cause of death was water intoxication, and not malaria. Plasma levels of dihydroartemisinin were noted to be high in this patient although this was not thought to have accounted for his death. (This is further addressed in the section on safety.)
The final clinical outcome at 24 hours, according to the FDA-defined endpoints is summarized in the table below.
Table 11: Clinical and parasitological outcomes at 24 hours, according to FDA defined
endpoints
|
Location (Study No.) |
||
|
Thailand (005)* |
Malawi (006)** |
South Africa (007)* |
Randomized Artesunate Comparator |
46 17 |
87 22 |
27 9 |
Excluded Artesunate Comparator |
5 3 |
3 0 |
1 1 |
Clinical Failures Artesunate Comparator |
11 4 |
8 0 |
1 2 |
24-hr clinical success rate Artesunate Comparator 95% CI Artesunate –
Comp. P –value*** |
30/41 (73%) 10/14 (71.4%) (-26.9, 36.9) 1.0000 |
76/84 (90.5%) 22/22 (100%) (-38.6, 14.3) 0.2006 |
25/26 (96%) 6/8 (75%) (-16.5, 95.9) 0.1310 |
24-hr parasitological success rate Artesunate Comparator 95% CI Artesunate –
Comp P –value*** |
30/41 (73%) 10/14 (71.4%) (-26.9, 36.9) 1.0000 |
74/84 (88%) 3/22 (13.6%) (42.1, 80.2) <0.0001 |
22/26 (84.6%) 2/8 (25%) (15.3, 87.9) 0.0034 |
* Rescue was permitted in both arms in these studies
** Rescue was only permitted in the AS arm in this study.
*** Exact confidence interval and Fishers Exact Test
Following completion of treatment, patients were to be followed for 28 days from the time of study entry. During this time, weekly visits were scheduled and in addition, patients with a recurrence of clinical symptoms were seen at the time when they presented to study centers. The attendance at these follow-up visits was poor. For example, in Study 006, 55% of the patients in the artesunate arm and 73% of patients in the control arm did not attend the 28-day follow-up visit. For Studies 005 and 007 the number of patients lost to follow-up by Day 28 was not available.
Since the study centers also served as the local clinical treatment centers, we assumed that in general, subjects who did not report to the clinic between the day that therapy was completed and Day 28 were clinically well. However, we can not exclude the possibility that several of the patients lost to follow-up may have developed malaria.
The 28-day recrudescence/new infection rate was calculated based on the number of patients initially enrolled, and the number of patients with a laboratory confirmed recurrence of parasitemia.
Table 12:
28-day recrudescence/reinfection rates per number of patients enrolled in the study:
|
Location (Study No.) |
||
|
Thailand (005)* |
Malawi (006)* |
South Africa (007)* |
28-day recrudescence/ reinfection rate Artesunate Comparator |
0/41 (0%) 0/14 (0%) |
39/86 (45.3%) 5/22 (22.7%) |
2/26 (8%)** 2/8 (25%)** |
* Number of patients lost to follow-up is not available, thus the denominator represents the number of patients randomized. Patients with missing data are assumed not to have developed recrudescent malaria for the purpose of this analysis.
** Recrudescence diagnosed by PCR only, smears negative
These rates are presumed to reflect the combined efficacy of rectal artesunate or the comparator drug plus the efficacy of the follow up regimen. This is turn is related to the prevalent drug sensitivity of P. falciparum in the region where the study was conducted. In general, resistance to Fansidar is more common than resistance to mefloquine. This may account in part for the low recrudescence rates in study 005 compared to studies 006 and 007.
Parasitological clearance
The figures below show individual subject-level parasite counts over time for each of the pivotal studies. Results for the experimental arm and the control arm are show separately.
While these results demonstrate the rapid parasite clearance in most subjects
treated with artesunate, a small number of patients, described previously, who
failed to reach 60% of baseline parasitemia at 12 hours were given rescue
therapy. In study 005 there were 7
(17%) and 4 (29%) rescued subjects in the Artesunate and Quinine groups,
respectively. Study 006 had 3 (4%)
Artesuante subjects rescued and no provisions for rescue in the Quinine
group. Finally, Study 007 had 1 (4%)
and 2 (25%) rescued subjects in the Artesunate and Quinine groups,
respectively. Parasite counts obtained in these subjects after rescue are
included in the figures above. Although this analysis represents an unfairly
favorable parasitological response to therapy for the rescued subjects, the
fact that rescue was performed in both the arms of studies 005 and 007 permits
some comparison between the arms.
Study 14
Study 14 was a bioequivalence study to demonstrate the parasitological efficacy of three different formulations of rectal artesunate and did not provide comparative data with other antimalarial agents.
This three-arm study compared the formulation used in phase I and II studies, the formulation used in phase III studies, and the formulation proposed for marketing.
(A prior bioequivalence study in healthy male volunteers [Study 009] comparing these formulations failed to show equivalence for both AS and DHA. The intrasubject variability in Cmax and AUC for both AS and DHA was relatively high and ranged from 60 to 70%. The lack of adequate sensitivity of the assay resulted in a large number of non-measurable samples and lost data points, limiting the power for the analysis. Other potential reasons for variability in the study include: inconsistencies in rectal absorption, variability in the amount of drug substance absorption in the dosage form, variability in drug product quality, dissolution rate limitations from the formulation, and individual variability in drug metabolism. Study 14 was designed to address these difficulties.)
Table 13: Initial treatment in Study 14:
Moderately severe malaria |
Group A |
Rectal AS 2 x 200mg suppositories |
Group B |
4 x 100mg suppositories |
|
Group C |
1 x 400mg suppository |
Table 14: Consolidation regimens in Study 14
All groups (if able
to take orally) 24 hours after entry, oral artesunate (4 x 50mg tablets) for 3 days 24 hours after last dose of oral AS, 3 x 250mg tablets of mefloquine 48 hours after last dose of oral AS, 2 x 250mg tablets of mefloquine |
All groups (if
unable to take orally) 24 hours after entry, IV artesunate (120mg) then IV artesunate 60mg 12 hourly till able to tolerate oral medications and complete a total dose of 480-600mg artesunate 24 hours after last dose of oral AS, 3 x 250mg tablets of mefloquine 48 hours after last dose of oral AS, 2 x 250mg tablets of mefloquine |
The study was performed on 69 hospitalized adult patients (23 per arm) with moderately severe malaria.
Inclusion criteria required a baseline parasitemia $100,000/:l and/or non-per os status. Exclusion criteria resembled those for studies 005, 006, and 007 where patients with complicated malaria or decreased level of consciousness were not enrolled.
All 69 patients completed the study successfully without the need for rescue therapy.
Parasitemia was rapidly cleared as shown below:
Table 15: Median parasite counts /:l at 0, 12, 24 and 48 hours
|
Baseline |
12 hours |
24 hours |
48 hours |
Group A |
46,720 |
3,890 |
30 |
1 |
Group B |
30,960 |
9,980 |
86 |
0 |
Group C |
40,680 |
13,080 |
62 |
0 |
The mean fractional reduction in parasitemia at 24 hours for the 3 groups ranged from 83.1% to 97.3% and by 48 hours, all patients had effectively cleared parasites.
Fever clearance time was similar for all three groups with a mean of 21.6 hours in Group A, 21.9 hours in Group B and 24.8 hours in group C.
Data beyond 7 days were not described and recrudescence/new infection rates for this population are not known.
Studies 003 and 004
These were two randomized, open-label, crossover studies
between IV and rectal artesunate performed on hospitalized patients with
“moderately severe” malaria. These
studies were designed to provide both clinical and pharmacokinetic data. The WHO conducted population pharmacokinetic
analyses using pharmacokinetic data from both of these studies. The review of these analyses is currently
ongoing; therefore, the WHO's conclusions cannot be verified at this time.
The clinical data from
these studies are summarized in the following pages.
The treatment arms involved crossover between rectal and intravenous artesunate at 2 dosing strengths as shown in the table.
Table 16: Treatment arms in Studies 003 and 004
|
Location (Study No.) |
|
|
Thailand (003) |
Ghana (004) |
IV AS 2.4mg/kg After 12 hrs, Rectal AS 10mg/kg |
12 patients (Group 1) |
0 patients |
Rectal AS 10mg/kg After 12 hours IV AS 2.4mg/kg |
12 patients (Group 2) |
12 patients (Group 1) |
IV AS 2.4mg/kg After 12 hrs, Rectal AS 20mg/kg |
12 patients (Group 3) |
12 patients (Group 3) |
Rectal AS 20mg/kg After 12 hours IV AS 2.4mg/kg |
12 patients (Group 4) |
12 patients (Group 2) |
Notably none of these arms included initial rectal artesunate according to the proposed regimen (Rectal artesunate, 10mg/kg alone during the first 24 hours of therapy).
Table 17: Consolidation regimen for studies 003 and 004
|
Location (Study No.) |
|
|
Thailand (003) |
Ghana (004) |
“consolidation therapy” |
Mefloquine at 36 and 48 hours |
Chloroquine over 3 days (sulfadoxine-pyrimethamine if intolerant of chloroquine) |
Table 18: Inclusion and exclusion criteria for studies 003 and 004
Thailand (003) |
Ghana (004) |
Inclusion criteria |
|
Adults 16-50 years |
Children 18 months to 7 years |
Entry parasite count ³ 100,000 /:l |
Entry parasite count ³ 10,000 /:l |
Non per-os patient |
Non per-os patient |
No vital organ dysfunction |
|
Exclusion criteria |
|
Cerebral malaria or complicated malaria (e.g. pulmonary edema, renal failure, shock) |
Cerebral malaria (coma £ 2 on Blantyre scale) hypoglycemia, blood lactate ³ 5 mmol/l or Hct < 15% |
Rectal abnormalities/acute diarrhea |
Rectal abnormalities/acute diarrhea |
|
Previous antimalarial treatment |
Short term (24-hour) clinical outcome:
Patients given the same initial treatment regimens were pooled
and the clinical outcome at 24 hours was determined as successful if the
patient completed treatment and did not require “rescue” therapy with
additional antimalarial drugs.
Table 19: 24-hour clinical success rates
Regimen |
Short term clinical success |
IV AS 2.4 mg/kg, Rectal AS 10 mg/kg |
12/12 |
Rectal AS 10 mg/kg, IV AS 2.4 mg/kg |
23/24 |
IV AS 2.4 mg/kg, Rectal AS 20 mg/kg |
22/23 |
Rectal AS 20 mg/kg, IV AS 2.4 mg/kg |
22/24 * |
*In this treatment group, 2 patients progressed clinically to severe malaria
Short term (24 hour)
parasitological outcome
Table 20: Pooled parasitological results showing the numbers of patients with ³90% reduction of baseline parasitemia at 12 and 24 hours:
Regimen |
12 hours |
24 hours |
IV AS 2.4 mg/kg, Rectal AS 10 mg/kg |
1/12 |
8/12 |
Rectal AS 10 mg/kg, IV AS 2.4 mg/kg |
5/23 |
21/23 |
IV AS 2.4 mg/kg Rectal AS 20 mg/kg |
5/23 |
20/22 |
Rectal AS 20 mg/kg IV AS 2.4 mg/kg |
3/24 |
21/23 * |
*In this treatment group, 2 patients progressed
clinically to severe malaria
Recrudescences or new infections
Table 21:Recurrent parasitemia during the first 2 to 3 weeks after completion of therapy
|
Recrudescence rate among patients
allocated to treatment |
Mefloquine |
7/48 15% |
Chloroquine |
7/23 30% |
Sulfadoxine-pyrimethamine |
2/9 22% |
Discussion of efficacy results
In the studies described above, rectal artesunate results in a rapid clearance of parasites in most patients. The clearance of parasites is notably slower when quinine is used for treatment.
At 24 hours, the clinical outcome in the pivotal studies is similar for rectal artesunate and for comparator regimens.
It is unclear what the clinical outcome would have been without additional therapy in the small number of patients rescued for unsatisfactory parasitologic responses in the first 12 hours.
While these studies characterize the benefits of emergency rectal artesunate compared to standard therapy in the hospital setting, the benefits of emergency rectal artesunate compared to no treatment in the bush, without ancillary supportive therapy, are not directly determined. Such an evaluation should take into account the mortality of untreated, moderately severe malaria, which is estimated to be high.
By Day 28, high rates of recrudescence occur in some studies. This presumably depends in part on the follow-up regimen used and the prevalent patterns of drug resistance. However recrudescence rates appear higher for artesunate-treated patients than for comparator treated patients, even when both are given the same follow-up regimen. In evaluating the benefit of early treatment versus the risk of a higher recrudescence rate with rectal artesunate, the anticipated mortality from initial malaria versus recrudescent malaria should be considered. This may depend on several factors including access to medical attention and patients’ understanding of the disease.
(The
reader is referred to WHO’s Briefing Document pages 30-39 regarding safety and
the corresponding references. Direct
statements from the WHO’s application and safety briefing will be presented as Arial font in quotes.)
The applicant proposes to use artesunate rectally at the dose of 10 mg/kg x 1 in the initial treatment of malaria when the patient cannot tolerate oral route medications and parenteral administration is not available. In support of safety, three sets of data have been submitted as part of NDA 21-242, and a recent safety update, which contains data from an on-going field trial (Study 13, which is not part of this NDA review).
For the registration of artesunate as injection in 1989, there was one Phase 1 study with 26 healthy subjects, two phase 2 studies with 70 patients in total which also contained a control arm (Quinine IV) with 12 subjects, and 3 clinical studies with patients having varying degrees of falciparum malaria totaling 236 subjects. All of these studies were open-labeled and only one phase 2 study seems to have had a control arm. It appears that there were children included in the clinical studies but to what extent is unclear. There was one single-dose study, four multi-dose studies (4 dose over 3 days), and one 7-day study. The highest total dose (these are all intravenous doses) was in the 7-day study of 9.6 mg/kg. The clinical studies in ill patients all gave a total dose ranging from 4.8 to 6 mg/kg over a 3-day period. Adverse events described included bitter taste, mild pain at the injection site, bradycardia, paroxysmal ventricular premature beat, incomplete right bundle branch block, first-degree atrio-ventricular block, and urticaria. No major setbacks were due to safety issues with artesunate. The IV quinine group experienced tinnitus, deafness, nausea, dizziness, headache, and ECG abnormalities including bradycardia and incomplete right bundle branch block. Laboratory abnormalities described included decreased reticulocyte count on the 3rd day returning to baseline by the 7th day (in normal volunteers), increased SGOT, SGPT, and BUN, proteinuria, haematuria, and pyuria.
These documents with the corresponding commentaries are
supportive only. There were no datasets
submitted. Neither inspection nor
audits are possible at this time (over a decade later). Given these faacts, the applicant’s
interpretation was that the data collected by the Chinese investigators
provided “…
a favorable tolerability profile of artesunate. The drug was given through the
intravenous route on a variety of doses and up to a maximum of 7 days with no
major safety setbacks. Although not all of these trials were controlled and
none was blinded, they provide supportive data in support of the use of
artesunate for a limited indication.”
A systemic review of all available safety information from
published (n=151) and unpublished (n=18) studies was the second set of
supportive evidence submitted for review. The applicant’s summary included a
total of 15,567 patients from 169 studies exposed to artemisinin derivatives,
with safety information on 13,639 patients from 130 studies across a spectrum
of disease. In the artesunate safety
database, there was a total of 6258 patients with the majority coming from studies
in uncomplicated malaria (n=5485).
There were 417 patients in studies for severe malaria, 10 in moderate
malaria, and 1346 in “other”. The Systemic Review does not cover the dosage
used in these studies. However, from
the available literature, the highest total dose used for rectal artesunate was
45.71mg/kg given over 4 days divided in 8 doses in adult patients and 57 mg/kg
total dose given over 3 days in 3 divided doses in children. The number of patients exposed to these
doses was small, both sets of patients being < 30. Adverse events described include few cases of bitter taste, pain
at the injection site, fever and slight burning sensation as adverse events
seen in studies on healthy normal volunteers.
For comparative studies, the review describes the most commonly reported
adverse events (in the order of <1%) to be mild gastrointestinal (nausea,
vomiting, diarrhea, abdominal pain) events.
In severe malaria, artemisinin derivatives had fewer incidences of hypoglycemia,
skin reactions (pruritis, urticaria, rash), tinnitus, and dizziness than
quinine. In uncomplicated malaria,
pruritis was more common with chloroquine, nausea, dizziness, and tinnitus more
common with quinine, and vomiting more common with mefloquine than artemisinin
derivatives. Laboratory abnormalities
described include neutropenia, reticulocytopenia, eosinophilia, anemia,
transaminitis, culture-negative pyuria, hemoglobinuria, ECG
abnormal-bradycardia, and prolongation of QT interval in the order of 1% of the
tests done. There were a few cases of
elevated bilirubin, atrial extra-systoles and T-wave abnormalities. The vast
majority of the studies included in the Systemic Review did not have
neurological assessments done. However
of the available information, dizziness was the most common neurological
adverse event. Thus far, there is a
lack of evidence to suggest an association between artemisinin derivatives and
increased neurological deficits/sequelae.
There are obvious methodological deficiencies of compiling
published and unpublished data (with no available raw data) from various
studies over a span of time. Some of
those deficiencies which make the synthesis of the data problematic may include
variation in study design and quality, inadequate data collection, subjects
representing different disease severity (especially since many of the side
effects of the drug may be similar to the actual disease manifestations of
malaria) and the uncertainty of pooling adverse events from individual studies
to come up with an overall incidence.
Given that, this systemic review is “the most comprehensive attempt to
identify all the available information on the safety of artemisinin-type
compounds”. There were few side effects reported with these compounds overall
in the available literature and these side effects were mainly mild and
transient.
This safety dataset consisted of 14 study protocols and 13
study reports of which 2 were bioavailibility studies, 2 were bioequivalency
studies, 3 were pediatric “pivotal” studies, 3 adult “pivotal” studies, and 3
supportive (re-analyzed raw data from published literature) studies. The total safety database for subjects
exposed to rectal artesunate was 501 subjects (all hospitalized patients mainly
in Southeast Asia and Africa) which included 135 healthy volunteers, 275
patients with moderately severe disease and 91 patients with severe
malaria. One hundred sixty-six of these
patients were children and all of them had the diagnosis of moderately severe
malaria. All pharmacokinetic and
“pivotal” studies were one rectal dose studies with a majority receiving 10
mg/kg x 1 dose with a range of 6.8 to 22.2 mg/kg. Repeated dosing with rectal artesunate was given in the
supportive studies (Studies 10, 11, and 12) over 3 to 4 days with mean total
doses between 25- and 32 mg/kg dose with a range of 11.3 to 45.7 mg/kg. If all formulations of artesunate
administered in these studies are viewed collectively, the maximum dose
exposure for adults was 45.7 mg/kg total dose given over 4 days in 8 divided
doses. For children, the maximum dose
exposure was 21.4 mg/kg and the longest duration of exposure was 7 days (rectal
dose x 1 followed by oral dosing). In
the literature, the highest total rectal artesunate dosage used was 57 mg/kg
given over 3 days in daily divided doses.
The integrated adverse event count from one-dose rectal studies (this excludes multiple dose supportive Studies 10-12) yielded 63 adverse events in 219 adults receiving single dose rectal artesunate verses 34 adverse events from 14 comparator regimens (all IV quinine in Study 7: patients with severe malaria). Adverse event incidence comparison is not possible for the adult patients due to the extremely small number and type (severe disease patients only) of comparator cases. The numbers and type of adverse evnets (all children had diagnosis of moderately severe malaria) for comparison are better for the pediatric population where 33 adverse events were reported in 166 children (19.9%) receiving rectal artesunate as compared to 10 adverse events in 39 (25.6%) comparator-group children (17 with PO artesunate and 22 with IV quinine). The leading adverse events reported were gastrointestinal in all groups (mostly vomiting, and abdominal pain). Collectively, central nervous system/neurologic adverse events were 10/166 (6%) in the rectal artesunate dosed pediatric patients vs. 2/39 (5%) in the comparator group. Of the three remaining supportive studies, only one study reported adverse events. Of the 9 adverse events reported, 8 were gastrointestinal in nature and 1 case of dizziness. In all, very few events led to treatment discontinuation and were classified as treatment emergent or serious in nature.
There were 7 deaths (1.4%) out of the 501 patients in the
total safety database or 1/275 (0.36%) in patients with moderately severe
malaria and 6/91 (6.6%) in patients with severe malaria. These are within rates for patients treated
in a hospitalized setting. Overall, the
reported mortality rates in the literature range from 0.1% in the uncomplicated
malaria diagnosis to up to 40% for severe disease with cerebral malaria in
areas with poor access to care. The single pediatric death occurred in a 3-year
old boy in Study 5 who received rectal artesunate (11.5 mg/kg). The probable cause of death was determined
by the study investigators and the WHO reviewers to be due to “water
intoxication”. The narrative and the
chemistry laboratory values (i.e., his serum sodium decreased from 139 to 117
over 2 hours) corroborate this as likely.
Although the applicant surmised that the PK analyses “indicated that
rectal AS administration was felt not to be likely related to the death of the
patient”, his dihydroartemisin (DHA) level at both 2 hours and 4 hours
post dose was over 2 to 3 times the mean dose of children from Ghana (subject SA09: 2002 ng/ml at 2 hrs and 977
at 4 hrs compared to Ghana children 652 ± 353.2 ng/ml at 2 hrs and 396.8 ± 545.2 at 4 hrs) Since the metabolite DHA is
considered to be the most neurotoxic of all the artemisinin derivatives and in
light of the our lack of knowledge regarding the PK/PD of this drug in humans,
the high levels of DHA seen in this child at the time of death is
concerning. Nevertheless, the
investigator’s alternate explanation of death was satisfactory. Three other deaths occurred in another
pivotal trial (Study 7) and all three patients were in the group of patients
diagnosed with severe malaria. One
death was in the rectal artesunate arm and two deaths were in the IV quinine
arm. The investigator’s explanation for
these three deaths was underlying malarial disease with inadequate supportive
care in all three cases. The narratives
are consistent with the investigator’s assessments. The last three death reports come from Study 10 (a supportive
study), which also had patients with severe malaria. Here however, the investigators were unable to offer a clear
explanation of the deaths since in all three cases, the patients had cleared
their parasitemia at the time of death.
Laboratory monitoring was limited. Only Study 3 recorded had comprehensive CBC, Chemistry and LFTs. Overall, there was a transient decrease in hematocrit at 12-24 hours with return to baseline levels by day 7 and reaching normal values by Day 28. Previous healthy human studies had shown mild reticulocytopenia in patients receiving artesunate however, reticulocyte levels were not measured in these studies. The transient decrease in hematocrit was not attributable to any treatment categories. Post-treatment, platelet counts, bilirubin levels, glucose and lactate levels gradually normalized. There were three patients with normal baseline levels whose SGOT and SGPT rose over 3 times above the upper limits of normal (not clinically symptomatic), peaked at Day 7-14, and started to come back down on day 21. Increased transaminases have been reported in the literature with many studies confounded by mefloquine co-administration. A preclinical toxicology study submitted with this application (Study No. BDC/002) did show liver toxicity (centrilobar hepatocyte hypertrophy, sinusoidal inflammatory cells, single cell necrosis and diffuse hepatocyte vacuolation) and it is known that artesunate’s major metabolite DHA is mainly cleared via glucuronidation. Thus, increased liver enzymes may be a related event with artesunate. However, this event has not translated thus far to symptomatic liver toxicity in known clinical experience. Only in Study 3 was ECG monitored. No significant abnormalities were noted.
With regards to pediatric patients, there were too few patients < 2 years old in these studies (8 out of 166 pediatric subjects) and the applicant is limiting the indication of this drug to patients older than 2 years of age at this time. Also, the applicant has not shown any data for the geriatric patient population (6 out of 335 adult subjects were above the age of 50). Specific studies in patients with hepatic and renal impairments were not performed. Pregnant patients were not included in any of the WHO-specific studies. Consistent findings of impaired fetal survival (but no evidence of teratogenicity) following first trimester exposure to artemisinins in animal studies are of concern. However, the applicant states:
“carefully conducted human studies have
not confirmed a level of toxicity or risk of teratogenicity attributable to the
artemisinins, and neither has evidence been demonstrated of other fetal injury
or impairment of maternal health over and above the effects on reproductive
health of malaria itself”.
Since neurotoxicity is considered a serious class effect for artemisinin derivatives (dose-related unique pattern of neuropathology showing necrosis of some neurons in vestibular, cochlear, olivary, red and other nuclei in the brainstem of animals), the applicant has attempted to address this issue by providing:
1) Non-clinical summary data from the Chinese studies,
2) Non-clinical WHO-commissioned toxicology studies performed by Quest of United Kingdom,
3) A 1998 WHO-sponsored expert review of all available pathological material as well as published and unpublished information,
4) Neurological assessments in clinical Studies 5, 6 and 7, and
5) Literature sources citing human clinical experience regarding neurological adverse events/sequelae.
The Chinese data (as per the FDA Toxicology Review) was mainly not interpretable and could not be validated. The WHO-commissioned toxicology data submission was disappointing (FDA had asked for a specific neurotoxicity study; however the submitted study was a 7-day rat toxicology study without specific neurotoxicology assays, staining, or behavioral assessments) and concerning (the high-dose arms were prematurely discontinued due to unexplained deaths; 1 /16 rat died on day 4 of 75 mg/kg dosing and 2/16 rats died on day 3 of 150 mg/kg dosing). The 1998 WHO sponsored expert review discussed neurotoxic effects of artemisinin derivatives in 3 animal species. The NOAEL for arteether and artemether in rats was thought to be at 45 – 75 mg/kg IM x 1 or over 7 days; in dogs at 3 – 6.25 mg/kg/day IM x 7 days; and in monkeys 100 mg/kg IM x 1 or over 7 days. The limited information for Artesunate did not show neuronal necrosis at 420 mg/kg x 1 IM or 200 mg/kg/day PO x 5-7 days.
The WHO briefing document states:
“The conclusion is that the administration of artesunate by the oral or intravenous route to the study animals at dose levels and duration that gave a total dose of 210-300 mg/kg (21-30 fold greater than the total proposed human dose) did not result in clinical or neuropathological findings, nor indicate any neurotoxic action”.
This direct dose comparison between animal and clinical
doses relating to safety margin (not accounting for body surface area) is
inappropriate. The body surface area
conversion of the rat dosages of 210-300 mg/kg provides equivalent human doses
of approximately 35-50 mg/kg, which is only 3 to 5 times the proposed 10 mg/kg
x 1 proposed human dose, not “21-30 fold greater” as claimed by the applicant. Body surface area conversion of the rat
dosages at which deaths occurred in the WHO-commissioned studies (75 and 150
mg/kg PO) provides equivalent human doses of approximately 12 and 25 mg/kg,
respectively, which considerably narrows the margin of safety.
Neurological assessments in WHO-specific clinical studies were performed for Studies 5, 6, and 7 only. This should provide data on approximately 164 rectal artesunate recipients tested (neurological assessments consisting of cranial nerves, nystagmus, hearing, tandem walking, the Romberg test, line drawing, picking tablets, rapid alternating movements, and finger tapping) out of the 501 total patients. However, missing data was extremely common and, according to the applicant, many of the young patients did not cooperate with the assessments. Nevertheless, no pattern of neurological abnormalities was concerning. The WHO’s main argument for the safety of artesunate and the lack of human neurotoxicity draws upon the large body of literature and the actual usage experience. The applicant states:
“careful neurological examinations have also been made in 1303 patients treated with the artemisinins, 806 in patients treated with artesunate….The analysis of a large body of clinical data by Price et al to assess patients treated with artemisinins, including dosing by the oral, intravenous, and rectal routes, did not identify any neurotoxic effects”.
Unfortunately, a closer look at the reference that the applicant is citing in the Briefing Document (Reference 14; Price et al 1999), identifies that it discusses patients with acute uncomplicated malaria, which is not the population that the applicant proposes to treat. Furthermore, the authors of the article write that “neurologic examinations could be performed reliably only in patients >5 years old”. It is very young children who are not able to take PO that the proposed indication will most likely include.
This leads us to a brief look at the 120-day Safety Update which contained data from Study 13 (a field study
that is on-going in Bangladesh, Ghana, and Tanzania) where the proposed
indication is being studied in placebo-controlled fashion and with patients as
young as 6 months of age. This study
remains blinded at this time. The
update highlights the fundamental differences in the populations between the
WHO-specific studies submitted to the NDA (e.g., all hospitalized patients, all
with proven malaria disease, mainly moderately-severe malaria disease, only 8
patients < 2 years of age) versus the on-going field study (patients at
remote sites, 74% of available malaria smears positive, 12% of patients
unconscious at baseline, 23% with repeated convulsions, and 1093/1947 (56%) of
patients enrolled in Ghana and Tanzania aged <2 years). Moreover, of the 16 patients thus far being
followed for neurological sequelae, only 50% had a positive malaria smear at
baseline and 25% had confirmed bacterial meningitis by cerebrospinal fluid
analysis (although not all had a lumbar puncture). The low incidence of neurological sequelae thus far (0.47%) is
reassuring. However, this safety update
calls attention to the likelihood that the population that the proposed
indication will actually serve will be very young children with severe malaria
disease and/or other severe disease such as bacterial meningitis. This is a population in whom little
information is available (even in the large body of clinical experience, and
certainly none in the actual WHO-specific studies of this NDA) to draw upon for
an adequate safety evaluation of artesunate.
Although we are in agreement with the applicant’s overall summary which stated:
“it is apparent that artesunate, whether given as a rectal dose of 10 mg/kg, 20 mg/kg (pivotal studies) or in a total rectal dose of 1200 mg or 1600 mg over 3 days followed by mefloquine (non pivotal studies) or in different formulations (oral or intravenous), has a highly favorable safety profile. The number of adverse events is small and, even if they were drug-related in such a severely ill group of patients, the incidence is very low. No consistent pattern of toxicity has been identified”,
we are mindful of the many uncertain safety issues including the as-of-yet undetermined safety margin for neurotoxicity in particular, and the as-of-yet undetermined safety parameters for the population that will be treated with the proposed indication in general. Nevertheless, as we consider the risk/benefit ratio, the cost of the disease malaria (especially with rising multi-drug resistant malaria) to individual human suffering and global public health becomes the paramount challenge to overcome. In this light, the use of artesunate at the dose and formulation proposed (10 mg/kg x 1) is within the safety limits of the collective currently available knowledge. However, the uncertainties and our concerns regarding safety would drastically expand if repeated dosing with rectal artesunate becomes an issue.